Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

• Main Authors: Jean Palussière, Vittorio Catena, Philippe Lagarde, Sophie Cousin, Mathilde Cabart, Xavier Buy, François Chomy
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2019-10-01
• Series: International Journal of Hyperthermia
• Subjects: Non-small cell lung cancer; thermal ablation; radiofrequency ablation; microwaves; cryoablation
• Online Access: http://dx.doi.org/10.1080/02656736.2019.1647351

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for patients with medical comorbidities and who are ineligible for surgery. In this context, stereotactic body radiotherapy (SBRT) has demonstrated high efficacy in treating T1 NSCLC and will need to be compared with percutaneous ablation. TA is also indicated in oligoprogressive disease; and can be proposed as a salvage treatment option for tumor recurrence after radiotherapy. Besides more advanced NSCLC could be also an indication of TA in combination with systemic treatments. A large majority of diagnosed NSCLC do not exhibit specific targetable genetic aberration. Those tumors present poorer prognosis and have been treated with standard chemotherapy regimen until the recent development of immune checkpoint inhibitors (ICIs) based immunotherapy. Combining TA with immunotherapy is promising and still needs to be explored.